KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) was the target of a significant decrease in short interest during the month of January. As of January 31st, there was short interest ...
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) has attracted significant investment activity from Venrock Healthcare Capital ...
This article summarizes the most significant insider buying and selling activities for US stocks reported on Friday, February ...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of ...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the presentation of novel data related to long-term ...
JMP Securities initiated coverage of KalVista (KALV) with an Outperform rating and $19 price target KalVista is developing sebetralstat, a small-molecule plasma kallikrein inhibitor, which could ...
KalVista Pharmaceuticals, Inc. has a twelve month low of $7.30 and a twelve month high of $16.88. The company’s 50 day moving average is $8.75 and its two-hundred day moving average is $10.58.
KalVista (KALV) announced that Japan’s Ministry of Health, Labour and Welfare, or MHLW, has granted sebetralstat orphan drug designation. The company has also submitted a new drug application ...
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Japan’s Ministry of Health, Labour and ...
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted ...